Compare DRD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | XNCR |
|---|---|---|
| Founded | 1895 | 1997 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2002 | 2013 |
| Metric | DRD | XNCR |
|---|---|---|
| Price | $26.72 | $24.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $32.63 | $22.33 |
| AVG Volume (30 Days) | 281.4K | ★ 1.3M |
| Earning Date | 08-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $39.23 | N/A |
| Revenue Next Year | $30.12 | $4.80 |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $19.47 | $8.29 |
| 52 Week High | $39.37 | $30.61 |
| Indicator | DRD | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 47.61 |
| Support Level | $26.37 | $11.20 |
| Resistance Level | $27.25 | $30.61 |
| Average True Range (ATR) | 0.84 | 1.60 |
| MACD | -0.39 | -0.69 |
| Stochastic Oscillator | 2.28 | 5.48 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.